New pill targets Hard-to-Treat cancers with hippo pathway mutations

NCT ID NCT06251310

Recruiting now Disease control Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safest dose; in the second part, they will check if the drug can shrink tumors. About 186 adults will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SW-682 (an oral tablet)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early (phase 1) trial with only 186 participants, so the drug may not work or could have serious side effects. It is not yet known if SW-682 will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant mesothelioma mesothelioma Mesothelioma, Malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR MESOTHELIOMA, MALIGNANT

Contacts and locations

Locations

HonorHealth Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
Mary Crowley Research Center US Oncology
RECRUITING

Dallas, Texas, 75230, United States
Oregon Health and Science University, Knight Cancer Institute - Marquam Hill
RECRUITING

Portland, Oregon, 97239, United States
U.T. MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
UC San Diego Moores Cancer Center
RECRUITING

Sacramento, California, 92093, United States
UCLA Hematology-Oncology - Santa Monica
RECRUITING

Santa Monica, California, 90404, United States
USC Norris Comprehensive Cancer Center and Hospital
RECRUITING

Los Angeles, California, 90033, United States
University Hospital of Cleveland
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.